Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2021 June;112(3) > Minerva Medica 2021 June;112(3):315-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

EDITORIAL   Freefree

Minerva Medica 2021 June;112(3):315-7

DOI: 10.23736/S0026-4806.21.07450-4

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Neuroendocrine neoplasms: what we have learned and what the future holds in the pharmacological treatment

Giovanni VITALE 1, 2 , Luigi BARREA 3, 4, Antonio AVERSA 5

1 IRCCS Istituto Auxologico Italiano, Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Cusano Milanino, Milan, Italy; 2 Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; 3 Unit of Endocrinology, Department of Clinical Medicine and Surgery, Medical School of Naples, Federico II University, Naples, Italy; 4 Unit of Endocrinology, Department of Clinical Medicine and Surgery, Centro Italiano per la Cura e il Benessere del Paziente con Obesità (C.I.B.O), Medical School of Naples, Federico II University, Naples, Italy; 5 Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy



top of page